Drawing for Serial No. 88514434

USPTO serial 88514434

Serial No. 88514434

Reviewed by CopyMark Law Group

Reg. 6342347Status 700Renewal
Filing date
Status date
Registration date
May 4, 2021
Examiner
FATHY, DOMINIC
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 88514434?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Paul C. Llewellyn

Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP250 West 55th StreetNew York, NY 10019-9710UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseasesACTIVEOct 15, 2014

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 4, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 4, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 2, 2021SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Apr 1, 2021CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 19, 2021SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Mar 19, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 1, 2021IUAFUSE AMENDMENT FILED—
Mar 1, 2021EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 17, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 15, 2020EX1GSOU EXTENSION 1 GRANTED—
Oct 15, 2020EXT1SOU EXTENSION 1 FILED—
Oct 15, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 21, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 25, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 25, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 5, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 17, 2020ALIEASSIGNED TO LIE—
Jan 14, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 13, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 13, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 13, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 2, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 2, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 30, 2019DOCKASSIGNED TO EXAMINER—
Aug 12, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 12, 2019COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 20, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jul 19, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 18, 2019TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jul 18, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 18, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance